Mycobacterium leprae

Background

Microbiology

• Slow-growing Gram-positive and acid-fast bacillus

Epidemiology

• About 1 million cases worldwide each year, but is rare in North America
  • Number may be underestimated due to difficulties with reliable diagnosis
• Most commonly occurs in Southeast Asia (especially India) and Brazil
• Decreasing incidence over the past several decades, likely due to short-course multidrug therapy starting in 1982
• Humans are thought to be the main reservoir, but it has been found in animals as well (particularly nine-banded armadillos)
• Transmitted most likely by respiratory droplets, though can also be transmitted by direct contact, transplacentally, through breast milk, and after animal exposure

Risk Factors

• Age, with peaks in adolescence and ≥30 years
• Adult men (compared to adult women)
• Duration of contact with an infected patient, and the burden of bacilli in the patient

Pathophysiology

• The clinical spectrum of disease depends on the host immune response to infection
• A robust Th1 CD4 response causes tuberculoid leprosy, which is paucibacillary and well-controlled
  • Requires interferon-γ
• A Th2 CD4 response causes lepromatous leprosy, which is multibacillary and more progressive

Clinical Presentation

• Following exposure, about 95% clear it spontaneously
• For those who do not, there is an incubation period of 3-5 years (with wide range) that is usually followed by indeterminate leprosy
  • Single, ill-defined, hypopigmented skin lesion
  • About 75% spontaneously resolve, with the other 25% progressing
• Classic presentation is anaesthetic hypopigmented skin lesion with thickened nerves
• Skin lesions can be: annular, asymmetric macules or plaques with central clearing and elevated borders (in tuberculoid) or symmetric, poorly-demarcated nodules and plaques or diffuse infiltration (lepromatous)
  • Lepromatous can also have xanthoma-likek or dermatofibroma-like lesions, leonine facies, and eyebrow alopecia

Spectrum of disease

• Clinical spectrum can be classified based on the number of lesions and burden of mycobacteria
  • Paucibacillary (PB) disease has 1 to 5 skin lesions, without bacilli on skin slit smear
  • Multibacillary (MB) disease has more than 5 skin lesions, with or without nerve involvement or bacilli on slit-skin smear (regardless of number of lesions)
• Can also be classified based on general clinical appearance
  • Tuberculoid leprosy (TT) corresponds to paucibacillary
  • Borderline tuberculoid leprosy (BT)
  • Borderline leprosy (BB)
  • Borerdline lepromatous leprosy (BL)
  • Lepromatous leprosy (LL) corresponding to multibacillary disease

Type I reaction

• A cell-mediated hypersensitivity reaction that can develop in the course of treatment
• Also known as a reversal reaction due to the apparent worsening of the lesion
• Occurs most commonly in the borderline cases and may signal progression to the cell-mediated tuberculoid end of the clinical spectrum

Type 2 reaction

• A humorally-mediated hypersensitivity reaction that can develop in the course of treatment
• Also known as erythema nodosum leprosum
• Characterized by systemic illness and immune-complex deposition that appears as groups of tender subcutaneous nodules
• May have other signs of vasculitis, including fevers, arthralgias, neuralgia, lymphadenopathy, orchitis, and dactylitis

Physical examination

Commonly affected nerves

Trunk	Palpation	Sensation	Movement	Deformity
Ulnar nerve	Just superior to medial epicondyle	Fifth digit and ulnar aspect of hand	Fifth digit abduction	Claw deformity of little and ring fingers
Median nerve	Palmar wrist just medial to palmaris longus	Lateral three fingers and palm	Thumb abduction	Claw deformity of first through third digits

Management

WHO recommendations

Disease	Treatment
Paucibacillary	6 months of rifampin, dapsone, and clofazimine
Multibacillary	12 months of rifampin, dapsone, and clofazimine
Rifampin resistance	6 months of at least two second-line drugs (below) with clofazimine, followed by 18 months of one second-line drug with clofazimine
Quinolone resistance	As for rifampin resistance, but without a fluoroquinolone

National Hansens's Disease Program (US)

Disease	Treatment
Tuberculoid (TT & BT) (i.e. paucibacillary)	12 months of dapsone and rifampicin
Lepromatous (LL, BL, and BB) (i.e. multibacillary)	24 months of dapsone, rifampicin, and clofazimine

Second-line antibiotics

• Clarithromycin
• Minocycline
• Fluoroquinolones: ofloxacin, levofloxacin, or moxifloxacin

Management of reactions

Reaction	Management
Reversal reaction limited to skin	monitor clinically
Reversal reaction involving nerves	corticosteroids with slow taper, and rifampin changed to monthly from daily
Other reversal reaction	corticosteroids based on clinical judgment
Erythema nodosum leprosum with neuritis	prednisone 1 mg/kg/day (40 to 60 mg/day), tapered over 2 to 4 weeks, possibly with thalidomide or clofazimine as a steroid-sparing agent
Mild erythema nodosum leprosum	thalidomide 50 to 100 mg nightly